Positive outcomes for multiple patient types: 6.5-year data from CheckMate 067
Bristol Myers Squibb
About the CPD course
This module will guide you through the key subgroup data from the 6.5-year analysis of the Phase III study CheckMate 067. Throughout; you will be given some points about the current treatment pathway to consider. At the end of the module; you will be asked a series of questions about the data.
We are a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are focused on helping millions of patients around the world in disease areas such as oncology, haematology, cardiology, immunology, fibrosis, and specialty medicines. Through our Research & Development organisation, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.